Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma

被引：1
|
作者：
Abramson, Jeremy S. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
来源：
TRANSPLANTATION AND CELLULAR THERAPY | 2022年 / 28卷 / 10期
关键词：
AXICABTAGENE CILOLEUCEL; TISAGENLECLEUCEL; OUTCOMES; MULTICENTER;
D O I：
10.1016/j.jtct.2022.09.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：621 / 622
页数：2
相关论文
共 50 条
  • [21] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
    Rejeski, Kai
    Perez, Ariel
    Sesques, Pierre
    Hoster, Eva
    Berger, Carolina
    Jentzsch, Liv
    Mougiakakos, Dimitrios
    Froelich, Lisa
    Ackermann, Josephine
    Buecklein, Veit
    Blumenberg, Viktoria
    Schmidt, Christian
    Jallades, Laurent
    Fehse, Boris
    Faul, Christoph
    Karschnia, Philipp
    Weigert, Oliver
    Dreyling, Martin
    Locke, Frederick L.
    von Bergwelt-Baildon, Michael
    Mackensen, Andreas
    Bethge, Wolfgang
    Ayuk, Francis
    Bachy, Emmanuel
    Salles, Gilles
    Jain, Michael D.
    Subklewe, Marion
    BLOOD, 2021, 138 (24) : 2499 - 2513
  • [23] Salvage Radiotherapy in Relapsed/ Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure
    Ababneh, Hazim
    Ng, Andrea
    Frigault, Matthew
    Abramson, Jeremy
    Johnson, Patrick
    Jacobson, Caron
    Patel, Chirayu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S414 - S414
  • [24] Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
    Ababneh, Hazim S.
    Ng, Andrea K.
    Frigault, Matthew J.
    Abramson, Jeremy S.
    Johnson, Patrick Connor
    Jacobson, Caron A.
    Patel, C. G.
    HAEMATOLOGICA, 2023, 108 (11) : 2972 - 2981
  • [25] CAR T-cell therapy in refractory large B-cell lymphoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (01): : E19 - E19
  • [26] Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma
    Rozental, Alon
    Chavez, Julio C.
    Sehovic, Marina
    Locke, Frederick L.
    Lazaryan, Aleksandr
    Nishihori, Taiga
    Khimani, Farhad
    Jain, Michael D.
    Shah, Bijal D.
    Extermann, Martine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
    Tomassetti, Sarah
    Chen, Robert
    Dandapani, Savita
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [28] FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    不详
    AMERICAN HEALTH AND DRUG BENEFITS, 2020, 13 (05): : 214 - 214
  • [29] Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
    Grana, Allison
    Gut, Natalia
    Williams, Kiersten
    Maakaron, Joseph
    Porter, Kyle
    William, Basem M.
    Vasu, Sumithira
    Penza, Sam
    Brammer, Jonathan E.
    Saad, Ayman
    Puto, Marcin
    Jaglowski, Samantha M.
    Roddy, Julianna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (04): : 238 - 245
  • [30] Efficacy of Salvage Radiotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Wang, S.
    Chen, J. Y.
    Cao, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E471 - E472
12345